PerkinElmer licenses CHO cell line to Trinomab Biotech

By The Science Advisory Board staff writers

February 4, 2021 -- PerkinElmer has licensed its Horizon Discovery Chosource Chinese hamster ovary (CHO)-K1GS knockout cell line to Trinomab Biotech in China to produce a human monoclonal antibody drug candidate to fight tetanus toxin.

Trinomab was able to develop its drug candidate utilizing Horizon's Chosource cell line, including a gene-editing glutamine synthetase knockout CHO K1 cell line and well-established GS expression system. A phase I clinical trial in Australia is expected to be completed in August 2021.

More than nine biotherapeutics expressed in the Chosource cell line have progressed to investigational new drug filings, according to PerkinElmer.


Copyright © 2021 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.